CELG News and Press, Celgene Corporation From 09/12/19

Quick Take Aprea Therapeutics ( APRE ) has filed to raise gross proceeds of up to $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. APRE is in Phase 3 trials for it...

A Phase 3 clinical trial, QUAZAR AML-001 , evaluating Celgene's (NASDAQ: CELG ) CC-486 (azacitidine) as maintenance therapy in newly diagnosed patients with acute myeloid leukemia (AML) who achieved first complete response (CR) or complete response with incomplete blood count recovery (CRi)...

Top-line analysis showed a highly statistically significant and clinically meaningful improvement in overall survival for CC-486 Celgene plans regulatory submissions beginning in 1H 2020 Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international pha...

Amgen ( AMGN ) announced quite a large acquisition by the end of August as it was laying down $13.4 billion to acquire Otezla. The deal looks fair, although one would expect a slightly lower deal tag, given that Celgene was a forced seller in this instance and a reported price tag came in mu...

Today, we want to share our analysis of Bellicum Pharmaceuticals ( BLCM ) with you. Over the last year, its stock largely fluctuated, falling from ~ $7 in September 2018 to $0.78 in August 2019. Recently, the company’s stock price grew by more than 20% after Baker Bros. disclosed its ...

Data to be presented include analyses of long-term efficacy and safety of ozanimod in adults with relapsing forms of multiple sclerosis and effects on biomarkers of disease activity Celgene Corporation (NASDAQ:CELG) today announced it will present 13 scientific abstracts, including ne...

Amgen (NASDAQ: AMGN) is about to get a piece of Celgene (NASDAQ: CELG) . Sort of. To ease the way for the pending acquisition of Celgene by Bristol-Myers Squibb (NYSE: BMY) to close, Celgene is selling its psoriasis and psoriatic drug Otezla to Amgen for a cool $13.4 billion. It's a ...

Bristol-Myers Squibb (NYSE: BMY) isn't having a great year. The big pharma stock has spent most of 2019 in negative territory. Many investors weren't happy with the decision to acquire Celgene (NASDAQ: CELG) . And BMS has experienced some clinical-study disappointments for its blockbust...

After the Federal Trade Commission (FTC) demanded Bristol-Myers Squibb (NYSE: BMY) sell its blockbuster Otezla to secure approval for its $74 billion acquisition of Celgene (NASDAQ: CELG) , a bidding war resulted in Amgen (NASDAQ: AMGN) agreeing to pay $13.4 billion in cash for the ps...

August 27, I updated subscribers on the Bristol-Myers ( BMY ) and Celgene ( CELG ) deal. It looked very attractive. Today, it looks even more attractive to me. Here are my three reasons to buy/add; 1) Bristol-Myers made a deal with Amgen (AMGN), contingent upon FTC consent decree and closing o...